Grace Therapeutics (GRCE) Capital Expenditures (2019 - 2024)

Grace Therapeutics has disclosed Capital Expenditures across 5 years of filings, most recently posting $22000.0 for Q1 2024.

• In Q1 2024, Capital Expenditures rose 175.0% year-over-year to $22000.0; the TTM figure through Mar 2024 stood at $22000.0 (up 29.41% YoY), while the FY2024 annual figure was $22000.0, up 29.41% from the prior year.
• Capital Expenditures came in at $22000.0 for Q1 2024 at Grace Therapeutics, up from $8000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $319000.0 in Q1 2020 to a low of $2000.0 in Q3 2022.
• Average Capital Expenditures over 4 years is $61000.0, with a median of $22000.0 recorded in 2024.
• Year-over-year, Capital Expenditures soared 89.47% in 2020 and jumped 175.0% in 2024.
• Over 4 years, Capital Expenditures stood at $33000.0 in 2020, then slumped by 93.94% to $2000.0 in 2022, then surged by 300.0% to $8000.0 in 2023, then jumped by 175.0% to $22000.0 in 2024.
• Per Business Quant data, the three most recent Capital Expenditures figures were $22000.0 in Q1 2024, $8000.0 in Q1 2023, and $2000.0 in Q3 2022.